(Thr (GalNAc) 4,7,15, Ser (GalNAc) 9,11) -IgA1 Hinge Region Peptide

O=C([C@@H](N)C(C)C)N1[C@H](C(N[C@H](C(N[C@H](C(N2[C@H](C(N3[C@H](C(N[C@H](C(N4[C@H](C(N[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N6[C@H](C(N7[C@H](C(N[C@H](C(N8[C@H](C(N[C@H](C(N9[C@H](C(N[C@H](C(N)=O)CO)=O)CCC9)=O)CO)=O)CCC8)=O)[C@@H](C)O[C@H]%10O[C@@H]([C@@H]([C@@H]([C@H]%10NC(C)=O)O)O)CO)=O)CCC7)=O)CCC6)=O)[C@@H](C)O)=O)CO[C@H]%11O[C@@H]([C@@H]([C@@H]([C@H]%11NC(C)=O)O)O)CO)=O)CCC5)=O)CO[C@H]%12O[C@@H]([C@@H]([C@@H]([C@H]%12NC(C)=O)O)O)CO)=O)CCC4)=O)[C@@H](C)O[C@H]%13O[C@@H]([C@@H]([C@@H]([C@H]%13NC(C)=O)O)O)CO)=O)CCC3)=O)CCC2)=O)[C@@H](C)O[C@H]%14O[C@@H]([C@@H]([C@@H]([C@H]%14NC(C)=O)O)O)CO)=O)CO)=O)CCC1

[1]Nakamura I, et al. Detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients by using synthetic hinge peptide and glycopeptide probes. Nephrology (Carlton) . 2004;9 (1) :26-30.